| Source: HalifaxProj(inhibit) CGL-CS |
| Type: |
| Phosphatidylinositol 3-kinase (PtdIns3K or PI3K) is a family of enzymes that play a crucial role in cell signaling pathways, particularly in the regulation of cell growth, survival, and metabolism. The PI3K pathway is one of the most frequently altered pathways in human cancer.
Inhibition of the PI3K pathway has been explored as a therapeutic strategy for cancer treatment. Several PI3K inhibitors have been developed and are currently being tested in clinical trials. These inhibitors can target specific components of the pathway, such as PI3K, AKT, or mTOR. Class I phosphoinositide 3-kinase (PI3K) Class III PtdIns3K In contrast to the class III PtdIns3K as a positive regulator of autophagy, class I PI3K-AKT signaling has an opposing effect on the initiation of autophagy. PI3K inhibitors include: -Idelalisib , Copanlisib, Alpelisib -LY294002? -Wortmannin: potent PI3K inhibitor, has some associated toxicity. -Quercetin: -Curcumin -Resveratrol -Epigallocatechin Gallate (EGCG) |
| 1469- | SFN, | Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vivo, | Pca, | NA |
| 1475- | SFN, | Form, | Combination of Formononetin and Sulforaphane Natural Drug Repress the Proliferation of Cervical Cancer Cells via Impeding PI3K/AKT/mTOR Pathway |
| - | in-vitro, | Cerv, | HeLa |
| - | in-vitro, | BrCC, | H720 | - | in-vivo, | BrCC, | NA | - | in-vitro, | BrCC, | H727 |
| 4203- | SIL, | Unlocking the Neuroprotective Potential of Silymarin: A Promising Ally in Safeguarding the Brain from Alzheimer’s Disease and Other Neurological Disorders |
| - | Review, | NA, | NA |
| 3323- | SIL, | Anticancer therapeutic potential of silibinin: current trends, scope and relevance |
| - | Review, | Var, | NA |
| 3289- | SIL, | Silymarin: a promising modulator of apoptosis and survival signaling in cancer |
| - | Review, | Var, | NA |
| 3288- | SIL, | Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations |
| - | Review, | Var, | NA |
| 978- | SIL, | A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment |
| - | Review, | NA, | NA |
| 2415- | SK, | Shikonin induces programmed death of fibroblast synovial cells in rheumatoid arthritis by inhibiting energy pathways |
| - | in-vivo, | Arthritis, | NA |
| 2355- | SK, | Pharmacological properties and derivatives of shikonin-A review in recent years |
| - | Review, | Var, | NA |
| 2370- | SK, | The role of pyruvate kinase M2 in anticancer therapeutic treatments |
| - | Review, | Var, | NA |
| 2360- | SK, | Shikonin inhibits growth, invasion and glycolysis of nasopharyngeal carcinoma cells through inactivating the phosphatidylinositol 3 kinase/AKT signal pathway |
| - | in-vitro, | NPC, | HONE1 | - | in-vitro, | NPC, | SUNE-1 |
| 2194- | SK, | Efficacy of Shikonin against Esophageal Cancer Cells and its possible mechanisms in vitro and in vivo |
| - | in-vitro, | ESCC, | Eca109 | - | in-vitro, | ESCC, | EC9706 | - | in-vivo, | NA, | NA |
| 2188- | SK, | Molecular mechanism of shikonin inhibiting tumor growth and potential application in cancer treatment |
| - | Review, | Var, | NA |
| 2224- | SK, | Shikonin induces apoptosis and autophagy via downregulation of pyrroline-5-carboxylate reductase1 in hepatocellular carcinoma cells |
| - | in-vitro, | HCC, | SMMC-7721 cell | - | in-vitro, | HCC, | HUH7 | - | in-vitro, | HCC, | HepG2 |
| 2220- | SK, | Shikonin Alleviates Gentamicin-Induced Renal Injury in Rats by Targeting Renal Endocytosis, SIRT1/Nrf2/HO-1, TLR-4/NF-κB/MAPK, and PI3K/Akt Cascades |
| - | in-vivo, | Nor, | NA |
| 3043- | SK, | Shikonin Induces Apoptosis by Inhibiting Phosphorylation of IGF-1 Receptor in Myeloma Cells. |
| - | in-vitro, | Melanoma, | RPMI-8226 |
| 5103- | SK, | Attenuation of PI3K-Akt-mTOR Pathway to Reduce Cancer Stemness on Chemoresistant Lung Cancer Cells by Shikonin and Synergy with BEZ235 Inhibitor |
| - | in-vitro, | NSCLC, | A549 |
| 4216- | SSE, | Selenium ameliorates mercuric chloride-induced brain damage through activating BDNF/TrKB/PI3K/AKT and inhibiting NF-κB signaling pathways |
| - | in-vitro, | NA, | NA |
| 5076- | SSE, | Sodium selenite inhibits the growth of cervical cancer cells through the PI3K/AKT pathway |
| - | in-vivo, | Cerv, | HeLa | - | in-vivo, | Cerv, | SiHa |
| 5110- | SSE, | Autophagy inhibition through PI3K/Akt increases apoptosis by sodium selenite in NB4 cells |
| - | in-vitro, | AML, | APL NB4 |
| 5331- | TFdiG, | Anti-Cancer Properties of Theaflavins |
| - | Review, | Var, | NA |
| 5336- | TFdiG, | Theaflavin-3,3′-Digallate Protects Cartilage from Degradation by Modulating Inflammation and Antioxidant Pathways |
| - | in-vivo, | Nor, | NA |
| 1019- | TQ, | Thymoquinone suppresses migration of LoVo human colon cancer cells by reducing prostaglandin E2 induced COX-2 activation |
| - | vitro+vivo, | CRC, | LoVo |
| 2127- | TQ, | Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways |
| - | Review, | GBM, | NA |
| 2138- | TQ, | Thymoquinone has a synergistic effect with PHD inhibitors to ameliorate ischemic brain damage in mice |
| - | in-vivo, | Nor, | NA |
| 2084- | TQ, | Thymoquinone, as an anticancer molecule: from basic research to clinical investigation |
| - | Review, | Var, | NA |
| 2106- | TQ, | Cancer: Thymoquinone antioxidant/pro-oxidant effect as potential anticancer remedy |
| - | Review, | Var, | NA |
| 1935- | TQ, | Potential anticancer properties and mechanisms of thymoquinone in osteosarcoma and bone metastasis |
| - | Review, | OS, | NA |
| 3407- | TQ, | Thymoquinone and its pharmacological perspective: A review |
| - | Review, | NA, | NA |
| 3397- | TQ, | Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer |
| - | Review, | CRC, | NA |
| 3425- | TQ, | Advances in research on the relationship between thymoquinone and pancreatic cancer |
| 3427- | TQ, | Chemopreventive and Anticancer Effects of Thymoquinone: Cellular and Molecular Targets |
| 3422- | TQ, | Thymoquinone, as a Novel Therapeutic Candidate of Cancers |
| - | Review, | Var, | NA |
| 3431- | TQ, | PI3K-AKT Pathway Modulation by Thymoquinone Limits Tumor Growth and Glycolytic Metabolism in Colorectal Cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW48 |
| 3423- | TQ, | Epigenetic role of thymoquinone: impact on cellular mechanism and cancer therapeutics |
| - | Review, | Var, | NA |
| 3559- | TQ, | Molecular signaling pathway targeted therapeutic potential of thymoquinone in Alzheimer’s disease |
| - | Review, | AD, | NA | - | Review, | Var, | NA |
| 3573- | TQ, | Chronic diseases, inflammation, and spices: how are they linked? |
| - | Review, | Var, | NA |
| 5020- | UA, | Anticancer activity of ursolic acid on human ovarian cancer cells via ROS and MMP mediated apoptosis, cell cycle arrest and downregulation of PI3K/AKT pathway |
| - | in-vitro, | Ovarian, | NA |
| 4869- | Uro, | Urolithin A in Central Nervous System Disorders: Therapeutic Applications and Challenges |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 4862- | Uro, | Neuroprotective effect of Urolithin A via downregulating VDAC1-mediated autophagy in Alzheimer's disease |
| - | in-vivo, | AD, | NA | - | in-vitro, | Nor, | PC12 |
| 4833- | Uro, | Unveiling the potential of Urolithin A in Cancer Therapy: Mechanistic Insights to Future Perspectives of Nanomedicine |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | IBD, | NA |
| 4837- | Uro, | Urolithins: The Gut Based Polyphenol Metabolites of Ellagitannins in Cancer Prevention, a Review |
| - | Review, | Var, | NA |
| 4853- | Uro, | Urolithin A, a novel natural compound to target PI3K/AKT/mTOR pathway in pancreatic cancer |
| - | vitro+vivo, | PC, | MIA PaCa-2 | - | in-vitro, | NA, | PANC1 |
| 4855- | Uro, | Urolithins impair cell proliferation, arrest the cell cycle and induce apoptosis in UMUC3 bladder cancer cells |
| - | in-vitro, | Bladder, | UMUC3 |
| 3135- | VitC, | The interplay between vitamin C and thyroid |
| - | Review, | Thyroid, | NA |
| 2365- | VitD3, | Vitamin D Affects the Warburg Effect and Stemness Maintenance of Non- Small-Cell Lung Cancer Cells by Regulating the PI3K/AKT/mTOR Signaling Pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1975 | - | in-vivo, | NA, | NA |
| 2283- | VitK2, | Vitamin K Contribution to DNA Damage—Advantage or Disadvantage? A Human Health Response |
| - | Review, | Var, | NA |
| 2281- | VitK2, | The biological responses of vitamin K2: A comprehensive review |
| - | Review, | Var, | NA |
| 1214- | VitK2, | Vitamin K2 promotes PI3K/AKT/HIF-1α-mediated glycolysis that leads to AMPK-dependent autophagic cell death in bladder cancer cells |
| - | in-vitro, | Bladder, | T24/HTB-9 | - | in-vitro, | Bladder, | J82 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:252 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid